The global Infertility Services market size was valued at US$ 7399 million in 2024 and is forecast to a readjusted size of USD 12050 million by 2031 with a CAGR of 7.2% during review period.
Infertility services refer to medical procedures and treatments that are designed to help individuals or couples who are experiencing difficulties in conceiving a child. These services aim to diagnose and treat the underlying causes of infertility, and potentially assist in achieving a successful pregnancy.
Infertility services have become an important part of the global medical field in recent years. With the change of lifestyle, the influence of environmental factors and the change of fertility concepts, infertility has gradually become an important social and health issue worldwide. According to statistics from the World Health Organization (WHO), about 10-15% of couples in the world face infertility problems. This proportion varies in different countries and regions, but the prevalence of this problem has prompted the rapid development of the infertility treatment market.
At present, the scale of the infertility service market is growing globally and is expected to continue to grow in the next few years. The rapid development of assisted reproductive technology (ART) has given hope to many couples who were once unable to get pregnant. The maturity of technologies such as in vitro fertilization (IVF), egg freezing, intracytoplasmic sperm injection (ICSI), and embryo genetic screening (PGS/PGD) has not only increased the success rate, but also allowed more infertile patients to enjoy treatment. In addition, with the advancement of genetic testing technology, the popularization of preimplantation genetic screening can effectively reduce the risk of chromosomal abnormalities and increase the chance of successful pregnancy.
Despite the rapid growth of the infertility service market, it still faces some challenges and problems:
High treatment costs: Assisted reproductive technologies such as IVF are expensive and not all families can afford them. Especially in some developing countries or regions, although the technology is gradually becoming popular, the cost of treatment is still a major obstacle. Therefore, how to reduce treatment costs and provide more economical treatment options is still a difficult problem that needs to be solved. Differences in technology accessibility: Although some advanced assisted reproductive technologies have been popularized in some developed countries, in many developing countries and regions, these technologies are not yet popular and the accessibility of treatment is low. In addition, the imbalance of medical facilities has caused a gap in the treatment of infertility in patients in different regions and industries.
With the continuous advancement of science and technology and the increase in social needs, the future development trend of the infertility service market is becoming clearer and clearer.
The core manufacturers of global infertility services include Ferring Pharmaceuticals, Merck, Jinxin Fertility, Vitrolife, Mayo Clinic and LIVZON. The top three manufacturers account for approximately 24% of the global share. The Asia-Pacific region is the world's largest market, accounting for nearly 45% of the market share.
In terms of product type, assisted reproductive technology (ART) occupies a dominant position, accounting for 62% of the market share. At the same time, in terms of application, females are the largest application field, accounting for 66%.
This report is a detailed and comprehensive analysis for global Infertility Services market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Infertility Services market size and forecasts, in consumption value ($ Million), 2020-2031
Global Infertility Services market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Infertility Services market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Infertility Services market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Infertility Services
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Infertility Services market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Ferring Pharmaceuticals, Merck, Jinxin Fertility, Vitrolife, Mayo Clinic, LIVZON, Abbott, Monash IVF, CARE Facility, Theramex, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Infertility Services market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Assisted Reproductive Technology (ART)
Infertility Drug Services
Others
麻豆原创 segment by Application
Male
Female
麻豆原创 segment by players, this report covers
Ferring Pharmaceuticals
Merck
Jinxin Fertility
Vitrolife
Mayo Clinic
LIVZON
Abbott
Monash IVF
CARE Facility
Theramex
TriHealth
NMC Health
CooperSurgical
Irvine Scientific
Virtus Health
CinnaGen
OB GYN Associates
Caerus Biotech
InVitroCare
INVO Bioscience
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Infertility Services product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Infertility Services, with revenue, gross margin, and global market share of Infertility Services from 2020 to 2025.
Chapter 3, the Infertility Services competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Infertility Services market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Infertility Services.
Chapter 13, to describe Infertility Services research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Infertility Services by Type
1.3.1 Overview: Global Infertility Services 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Infertility Services Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Assisted Reproductive Technology (ART)
1.3.4 Infertility Drug Services
1.3.5 Others
1.4 Global Infertility Services 麻豆原创 by Application
1.4.1 Overview: Global Infertility Services 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Male
1.4.3 Female
1.5 Global Infertility Services 麻豆原创 Size & Forecast
1.6 Global Infertility Services 麻豆原创 Size and Forecast by Region
1.6.1 Global Infertility Services 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Infertility Services 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Infertility Services 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Infertility Services 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Infertility Services 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Infertility Services 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Infertility Services 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Ferring Pharmaceuticals
2.1.1 Ferring Pharmaceuticals Details
2.1.2 Ferring Pharmaceuticals Major Business
2.1.3 Ferring Pharmaceuticals Infertility Services Product and Solutions
2.1.4 Ferring Pharmaceuticals Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Ferring Pharmaceuticals Recent Developments and Future Plans
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business
2.2.3 Merck Infertility Services Product and Solutions
2.2.4 Merck Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Merck Recent Developments and Future Plans
2.3 Jinxin Fertility
2.3.1 Jinxin Fertility Details
2.3.2 Jinxin Fertility Major Business
2.3.3 Jinxin Fertility Infertility Services Product and Solutions
2.3.4 Jinxin Fertility Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Jinxin Fertility Recent Developments and Future Plans
2.4 Vitrolife
2.4.1 Vitrolife Details
2.4.2 Vitrolife Major Business
2.4.3 Vitrolife Infertility Services Product and Solutions
2.4.4 Vitrolife Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Vitrolife Recent Developments and Future Plans
2.5 Mayo Clinic
2.5.1 Mayo Clinic Details
2.5.2 Mayo Clinic Major Business
2.5.3 Mayo Clinic Infertility Services Product and Solutions
2.5.4 Mayo Clinic Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Mayo Clinic Recent Developments and Future Plans
2.6 LIVZON
2.6.1 LIVZON Details
2.6.2 LIVZON Major Business
2.6.3 LIVZON Infertility Services Product and Solutions
2.6.4 LIVZON Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 LIVZON Recent Developments and Future Plans
2.7 Abbott
2.7.1 Abbott Details
2.7.2 Abbott Major Business
2.7.3 Abbott Infertility Services Product and Solutions
2.7.4 Abbott Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Abbott Recent Developments and Future Plans
2.8 Monash IVF
2.8.1 Monash IVF Details
2.8.2 Monash IVF Major Business
2.8.3 Monash IVF Infertility Services Product and Solutions
2.8.4 Monash IVF Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Monash IVF Recent Developments and Future Plans
2.9 CARE Facility
2.9.1 CARE Facility Details
2.9.2 CARE Facility Major Business
2.9.3 CARE Facility Infertility Services Product and Solutions
2.9.4 CARE Facility Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 CARE Facility Recent Developments and Future Plans
2.10 Theramex
2.10.1 Theramex Details
2.10.2 Theramex Major Business
2.10.3 Theramex Infertility Services Product and Solutions
2.10.4 Theramex Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Theramex Recent Developments and Future Plans
2.11 TriHealth
2.11.1 TriHealth Details
2.11.2 TriHealth Major Business
2.11.3 TriHealth Infertility Services Product and Solutions
2.11.4 TriHealth Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 TriHealth Recent Developments and Future Plans
2.12 NMC Health
2.12.1 NMC Health Details
2.12.2 NMC Health Major Business
2.12.3 NMC Health Infertility Services Product and Solutions
2.12.4 NMC Health Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 NMC Health Recent Developments and Future Plans
2.13 CooperSurgical
2.13.1 CooperSurgical Details
2.13.2 CooperSurgical Major Business
2.13.3 CooperSurgical Infertility Services Product and Solutions
2.13.4 CooperSurgical Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 CooperSurgical Recent Developments and Future Plans
2.14 Irvine Scientific
2.14.1 Irvine Scientific Details
2.14.2 Irvine Scientific Major Business
2.14.3 Irvine Scientific Infertility Services Product and Solutions
2.14.4 Irvine Scientific Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Irvine Scientific Recent Developments and Future Plans
2.15 Virtus Health
2.15.1 Virtus Health Details
2.15.2 Virtus Health Major Business
2.15.3 Virtus Health Infertility Services Product and Solutions
2.15.4 Virtus Health Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Virtus Health Recent Developments and Future Plans
2.16 CinnaGen
2.16.1 CinnaGen Details
2.16.2 CinnaGen Major Business
2.16.3 CinnaGen Infertility Services Product and Solutions
2.16.4 CinnaGen Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 CinnaGen Recent Developments and Future Plans
2.17 OB GYN Associates
2.17.1 OB GYN Associates Details
2.17.2 OB GYN Associates Major Business
2.17.3 OB GYN Associates Infertility Services Product and Solutions
2.17.4 OB GYN Associates Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 OB GYN Associates Recent Developments and Future Plans
2.18 Caerus Biotech
2.18.1 Caerus Biotech Details
2.18.2 Caerus Biotech Major Business
2.18.3 Caerus Biotech Infertility Services Product and Solutions
2.18.4 Caerus Biotech Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 Caerus Biotech Recent Developments and Future Plans
2.19 InVitroCare
2.19.1 InVitroCare Details
2.19.2 InVitroCare Major Business
2.19.3 InVitroCare Infertility Services Product and Solutions
2.19.4 InVitroCare Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.19.5 InVitroCare Recent Developments and Future Plans
2.20 INVO Bioscience
2.20.1 INVO Bioscience Details
2.20.2 INVO Bioscience Major Business
2.20.3 INVO Bioscience Infertility Services Product and Solutions
2.20.4 INVO Bioscience Infertility Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.20.5 INVO Bioscience Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Infertility Services Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Infertility Services by Company Revenue
3.2.2 Top 3 Infertility Services Players 麻豆原创 Share in 2024
3.2.3 Top 6 Infertility Services Players 麻豆原创 Share in 2024
3.3 Infertility Services 麻豆原创: Overall Company Footprint Analysis
3.3.1 Infertility Services 麻豆原创: Region Footprint
3.3.2 Infertility Services 麻豆原创: Company Product Type Footprint
3.3.3 Infertility Services 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Infertility Services Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Infertility Services 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Infertility Services Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Infertility Services 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Infertility Services Consumption Value by Type (2020-2031)
6.2 North America Infertility Services 麻豆原创 Size by Application (2020-2031)
6.3 North America Infertility Services 麻豆原创 Size by Country
6.3.1 North America Infertility Services Consumption Value by Country (2020-2031)
6.3.2 United States Infertility Services 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Infertility Services 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Infertility Services 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Infertility Services Consumption Value by Type (2020-2031)
7.2 Europe Infertility Services Consumption Value by Application (2020-2031)
7.3 Europe Infertility Services 麻豆原创 Size by Country
7.3.1 Europe Infertility Services Consumption Value by Country (2020-2031)
7.3.2 Germany Infertility Services 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Infertility Services 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Infertility Services 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Infertility Services 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Infertility Services 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Infertility Services Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Infertility Services Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Infertility Services 麻豆原创 Size by Region
8.3.1 Asia-Pacific Infertility Services Consumption Value by Region (2020-2031)
8.3.2 China Infertility Services 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Infertility Services 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Infertility Services 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Infertility Services 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Infertility Services 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Infertility Services 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Infertility Services Consumption Value by Type (2020-2031)
9.2 South America Infertility Services Consumption Value by Application (2020-2031)
9.3 South America Infertility Services 麻豆原创 Size by Country
9.3.1 South America Infertility Services Consumption Value by Country (2020-2031)
9.3.2 Brazil Infertility Services 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Infertility Services 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Infertility Services Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Infertility Services Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Infertility Services 麻豆原创 Size by Country
10.3.1 Middle East & Africa Infertility Services Consumption Value by Country (2020-2031)
10.3.2 Turkey Infertility Services 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Infertility Services 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Infertility Services 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Infertility Services 麻豆原创 Drivers
11.2 Infertility Services 麻豆原创 Restraints
11.3 Infertility Services Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Infertility Services Industry Chain
12.2 Infertility Services Upstream Analysis
12.3 Infertility Services Midstream Analysis
12.4 Infertility Services Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Ferring Pharmaceuticals
Merck
Jinxin Fertility
Vitrolife
Mayo Clinic
LIVZON
Abbott
Monash IVF
CARE Facility
Theramex
TriHealth
NMC Health
CooperSurgical
Irvine Scientific
Virtus Health
CinnaGen
OB GYN Associates
Caerus Biotech
InVitroCare
INVO Bioscience
听
听
*If Applicable.